Acadia Pharmaceuticals at a Glance

Acadia is committed to turning scientific promise into meaningful innovation that makes the difference for underserved neurological and rare disease communities around the world. We are developing the next wave of therapeutic advancements with a robust and diverse pipeline that includes mid- to late-stage programs in Alzheimer's disease psychosis and Lewy body dementia psychosis, along with earlier-stage programs that address other underserved patient needs. At Acadia, we're here to be their difference.

For more information visit us at Acadia.com or follow us on LinkedIn and X.

Acadia's Footprint

Year Founded: 1993 **Employees:** 900+

Acadia is headquartered in San Diego, California and Princeton, New Jersey, USA with offices in Toronto, Canada; Basel, Switzerland; Zug, Switzerland; and Amsterdam, Netherlands.

Corporate Milestones

Apr 2016	U.S. Food and Drug Administration (FDA) approves NUPLAZID® (pimavanserin)[1]
Aug 2018	Acadia enters into exclusive North American license agreement with Neuren Pharmaceuticals Ltd. for the development and commercialization of trofinetide[2]
May 2020	Acadia and Vanderbilt University announce exclusive license agreement and research collaboration to develop and commercialize novel drug candidates with potential to treat a range of central nervous system disorders
Jan 2022	Acadia and Stoke Therapeutics establish collaboration to pursue multiple RNA-based treatments for severe and rare genetic neurodevelopmental diseases[3]
Mar 2023	U.S. FDA approves DAYBUE® (trofinetide)[2]
Jul 2023	Acadia acquires ex-North American rights to trofinetide for Rett syndrome and global rights to NNZ-2591 (ACP-2591) from Neuren in Rett syndrome and Fragile X syndrome[2,4]
Nov 2023	Acadia announces initiation of Phase 2 trial evaluating remlifanserin (ACP-204) for the treatment of Alzheimer's disease psychosis[4]
Oct 2024	Health Canada approves DAYBUE[2]
Nov 2024	Acadia announces exclusive license agreement with Saniona for SAN711 (ACP-711) in essential tremor[4,5]
Dec 2025	U.S. FDA approves DAYBUE® STIX (trofinetide) for oral solution, a powder formulation of trofinetide[6]
Jan 2026	Ministry of Health in Israel approves DAYBUE[2]

[1]NUPLAZID (pimavanserin) is only approved in the U.S. by the FDA for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. [2]Acadia has an exclusive license to develop and commercialize trofinetide worldwide from Neuren Pharmaceuticals. DAYBUE (trofinetide) is only approved in the U.S. by the FDA, in Canada by Health Canada, and in Israel by the Ministry of Health for the treatment of Rett syndrome in adults and pediatric patients two years of age and older. [3]Acadia entered into a collaboration with Stoke Therapeutics to discover, develop and commercialize novel RNA-based medicines for the potential treatment of severe and rare genetic neurodevelopmental diseases; ASO = Antisense oligonucleotide. [4]Product candidates and investigational agents, for which the safety and efficacy of these agents have not been established. There is no guarantee these investigational agents will be filed with or approved by any regulatory agency. [5]Acadia entered into an exclusive worldwide license agreement with Saniona for the development and commercialization of ACP-711. [6]DAYBUE STIX (trofinetide) for oral solution, a powder formulation of trofinetide, is only approved in the U.S. by the FDA for the treatment of Rett syndrome in adult and pediatric patients two years of age and older.

Acadia Connect®

Acadia Connect is a free support program to help patients and caregivers navigate insurance, manage costs, and obtain information about financial assistance options.

Those enrolled are paired with a dedicated Care Coordinator who can offer insurance and prescription assistance options. Visit AcadiaConnect.com for more information. Terms and conditions apply.

Marketed Products - United States

NUPLAZID®
(pimavanserin) 34mg capsules

Please see full prescribing information, including **Boxed WARNING**, also available at Nuplazidhcp.com[1]

Daybue®
(trofinetide)

Please see full prescribing information available at Daybuehcp.com[2]

Pipeline

Acadia's pipeline is focused on high unmet needs in neurological and rare diseases. Our pipeline spans late to early and preclinical developments, including:

- Building upon the learnings of previous research in Alzheimer's disease psychosis, Acadia is developing remlifanserin, which is in Phase 2[3]
- Pursuing development of remlifanserin in an additional Phase 2 study for the treatment of Lewy Body Dementia psychosis[3]
- Investigating ACP-211 for Major Depressive Disorder, which is in Phase 2[3]
- Developing ACP-711 for essential tremor[3,4]
- Progressing development candidate ACP-2591 in Rett syndrome and Fragile X syndrome[3]
- Pursuing RNA based treatment for severe and rare genetic neurodevelopmental diseases through collaboration with Stoke Therapeutics[3,5]
- Developing a novel approach for improving cognitive function and other neuropsychiatric symptoms in patients with CNS disorders in collaboration with Vanderbilt University
- Investigating highly differentiated assets targeting tardive dyskinesia and Huntington's disease[3]

For our full pipeline, visit Acadia.com/pipeline.

[1]NUPLAZID (pimavanserin) is only approved in the U.S. by the FDA for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. [2]Acadia has an exclusive license to develop and commercialize trofinetide worldwide from Neuren Pharmaceuticals. DAYBUE (trofinetide) is only approved in the U.S. by the FDA, in Canada by Health Canada, and in Israel by the Ministry of Health for the treatment of Rett syndrome in adults and pediatric patients two years of age and older. [3]Product candidates and investigational agents, for which the safety and efficacy of these agents have not been established. There is no guarantee these investigational agents will be filed with or approved by any regulatory agency. [4]Acadia entered into an exclusive worldwide license agreement with Saniona for the development and commercialization of ACP-711. [5]Acadia entered into a collaboration with Stoke Therapeutics to discover, develop and commercialize novel RNA-based medicines for the potential treatment of severe and rare genetic neurodevelopmental diseases; ASO = Antisense oligonucleotide. Updated January 13, 2026; Acadia disclaims any duty to update.